RARE DISEASERESEARCH ATLAS

ORPHA:53693

GRACILE syndrome

medium confidenceDisorder

Also known as: Fellman disease · Growth restriction-aminoaciduria-cholestasis-iron overload-lactic acidosis-early death syndrome

Query health: suspect — Only one of 3 strategies returned hits (phrase).

Publications

153

65.5th percentile

Trials

0

Interventional, condition-specific

Researchers

896

Distinct authors in sample

Gene link

BCS1L

Definitive

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

An inherited lethal disorder characterized by fetal growth restriction (GR), aminoaciduria (A), cholestasis (C), iron overload (I), lactacidosis (L), and early death (E).

How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (1)

gracile syndrome

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Definitive — BCS1L

  2. LiteraturePresent

    153 matched papers (95 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (BCS1L).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

153

153 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

153 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

95 in the last 10 years · medium confidence · 65.5th percentile (publications denominator)

Phrase hits: 153 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

896

Distinct author names in 153 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Fellman V24 papers · 2026

    Pediatrics, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden.

    Papers in Europe PMC
  2. 02
    Kallijärvi J13 papers · 2026

    Folkhälsan Research Center, Helsinki, Finland.

    Papers in Europe PMC
  3. 03
    Zeviani M10 papers · 2025

    Mitochondrial Biology Unit, The MRC and University of Cambridge, Cambridge CB2 0XY, UK.

    Papers in Europe PMC
  4. 04
    Kotarsky H9 papers · 2020

    Pediatrics, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden.

    Papers in Europe PMC
  5. 05
    Purhonen J7 papers · 2026

    Folkhälsan Research Center, Haartmaninkatu 8, 00290, Helsinki, Finland.

    Papers in Europe PMC
  6. 06
    Costa R5 papers · 2022

    Department of Biology, University of Padova, Padova, Italy.

    Papers in Europe PMC
  7. 07
    Mörgelin M5 papers · 2023

    Division of Infection Medicine, Department of Clinical Sciences, Lund University, P.O.Box 117, 221 00, Lund, Sweden.

    Papers in Europe PMC
  8. 08
    Brischigliaro M4 papers · 2023

    Department of Biology, University of Padova, Padova, Italy.

    Papers in Europe PMC
  9. 09
    Dallabona C4 papers · 2025

    Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parco Area delle Scienze 11/A, 43124 Parma, Italy.

    Papers in Europe PMC
  10. 10
    Ghezzi D4 papers · 2021

    Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

medium confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"GRACILE syndrome" OR "Fellman disease" OR "Growth restriction-aminoaciduria-cholestasis-iron overload-lactic acidosis-early death syndrome"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Finnish lethal neonatal metabolic syndrome

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"GRACILE syndrome" OR "Fellman disease" OR "Growth restriction-aminoaciduria-cholestasis-iron overload-lactic acidosis-early death syndrome" OR "Finnish lethal neonatal metabolic syndrome" OR "BCS1L"

Recall-expansion terms: BCS1L

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: suspect — strategies attempted: phrase, mesh, recall-expansion; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is short or not clearly distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T00:53:26.784Z